Hamilton Wealth LLC Takes $678,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

Hamilton Wealth LLC acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 7,494 shares of the medical equipment provider’s stock, valued at approximately $678,000.

Several other large investors have also recently bought and sold shares of ZBH. PNC Financial Services Group Inc. lifted its stake in shares of Zimmer Biomet by 9.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares during the period. Morningstar Investment Management LLC boosted its holdings in Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after buying an additional 40,610 shares in the last quarter. Douglas Lane & Associates LLC grew its position in Zimmer Biomet by 6.7% during the fourth quarter. Douglas Lane & Associates LLC now owns 460,178 shares of the medical equipment provider’s stock worth $41,379,000 after buying an additional 28,818 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Zimmer Biomet by 257.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after buying an additional 24,748 shares during the period. Finally, CIBC Asset Management Inc increased its holdings in Zimmer Biomet by 67.6% in the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock valued at $4,183,000 after buying an additional 18,769 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $97.23 on Thursday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $18.81 billion, a P/E ratio of 25.26, a price-to-earnings-growth ratio of 2.82 and a beta of 0.46. The firm has a 50-day moving average price of $88.47 and a two-hundred day moving average price of $89.81. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 earnings per share. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 24.94%.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.28% of the company’s stock.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: UBS initiated coverage with a Buy rating and a $115 price target, implying substantial upside from recent trading levels. The firm cited Zimmer Biomet’s growth prospects and innovation, supporting optimism about its competitive position. Benzinga coverage
• Positive Sentiment: Recent coverage highlighted stronger quarterly revenue and described Zimmer Biomet as a top performer among diversified surgical-equipment companies. The company’s latest reported quarter also exceeded expectations, with earnings per share of $2.09 versus the $1.86 consensus and revenue of $2.09 billion versus $2.07 billion expected.
• Positive Sentiment: The stock is benefiting from renewed market confidence, with investors watching whether demand for orthopedic products, including knee and hip implants and robotic-assisted surgery systems, can support continued growth. Zimmer Biomet Gains Fresh Market Confidence
• Neutral Sentiment: Zimmer Biomet is approaching its second-quarter earnings release. Expectations call for modest revenue growth, making trends in knees, hips and surgical robotics especially important for the next market reaction. Zimmer Biomet Q2 Earnings Preview
• Negative Sentiment: Zacks Research downgraded the shares from Hold to Strong Sell, contrasting sharply with UBS and signaling concerns about valuation or the company’s growth outlook.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZBH. Leerink Partners assumed coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price target for the company. BMO Capital Markets assumed coverage on Zimmer Biomet in a report on Wednesday, July 8th. They issued a “market perform” rating and a $95.00 price target on the stock. Truist Financial reaffirmed a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Robert W. Baird set a $92.00 price objective on Zimmer Biomet in a report on Wednesday, April 29th. Finally, Citigroup decreased their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $102.00.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.